TLC (Taiwan Liposome Company) (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Endo International plc (Nasdaq: ENDP), through its subsidiary Endo Global Development Limited, today announced an agreement for the commercialization of a liposomal product under development by TLC.
Under the terms of the agreement, TLC will be responsible for the development and manufacturing of the product, including obtaining regulatory approval for the use, distribution, promotion and sale of the product in the United States. Upon TLC’s receipt of regulatory approval, Par Sterile Products, Endo’s sterile injectable business, will market, sell and distribute the product on an exclusive basis in the United States. TLC is eligible to receive upfront and subsequent milestone payments as well as a double-digit share of the net profits from product sales in the United States.
“Endo is committed to helping everyone we serve live their best life,” said Scott Sims, Senior Vice President and General Manager, Sterile Injectables of Endo. “We are focused on expanding and enhancing our portfolio and are pleased to be working with TLC, an innovator in the development of novel nanomedicines, on the delivery of medicines that will help hospitals and healthcare systems focus on patient care.”
“Following a series of recent good news, we are happy to be keeping the momentum going with yet another collaboration that combines the strengths of two outstanding companies,” commented TLC President George Yeh. “We are excited to be working with Endo, a company with a long history in injectables and branded therapeutics, making them the perfect fit for TLC. Along with TLC’s expertise and know-how in liposome technology, Endo’s deep commercial experience and market presence are crucial ingredients in our recipe for successful launch and commercialization of our products.”